[go: up one dir, main page]

SV2003000861A - Derivados de eteres utiles como agentes inhibidores de las isozimas pde4 ref. pc11896arms/bb - Google Patents

Derivados de eteres utiles como agentes inhibidores de las isozimas pde4 ref. pc11896arms/bb

Info

Publication number
SV2003000861A
SV2003000861A SV2002000861A SV2002000861A SV2003000861A SV 2003000861 A SV2003000861 A SV 2003000861A SV 2002000861 A SV2002000861 A SV 2002000861A SV 2002000861 A SV2002000861 A SV 2002000861A SV 2003000861 A SV2003000861 A SV 2003000861A
Authority
SV
El Salvador
Prior art keywords
rent
nr16r17
ilo
replaced
nr22ac
Prior art date
Application number
SV2002000861A
Other languages
English (en)
Inventor
Robert James Chambers
Thomas Victor Magee
Anthony Marfat
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of SV2003000861A publication Critical patent/SV2003000861A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPUESTOS UTILES COMO INHIBIDORES DE LA PDE4 EN EL TRATAMIENTO DE ENFERMEDADES REGULADAS POR LA ACTIVACION DE EOSINOFILOS ESPECIALMENTE ASMA, BRONQUITIS CRONICA Y ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA, DE LA FORMULA, VER FORMULA EN LA QUE J ES 0 O 1, CON LA CONDICION DE QUE CUANDO J ES 0, N DE BE SER 2; K ES 0 O 1; M ES 1,2 O 3; N ES 1 O 2; W1 Y W2 SON -O-; -S(=O)T-, EN QUE T ES 0,1 O 2, O -N(R3)-; Y ES =C(R1A)- O -[N-(O)K-EN QUE K ES 0 O 1; R1A ES -H, -F, -CL, -CN, -NO2, ALQUILO(C1-C4) ALQUINILO(C2-C4), ALQUILO(C1-C3)FLUORADO, ALCOXI(C1-C3)FLUORADO, -OR16, O -C(=O)NR22AR22B; RA Y RB SON -H, -F, CF3, ALQULO(C1-C4)CICLOALQUILO(C3-C7), FENILO O BENCILO SUSTITUIDO CON 0-3 R10; O RA Y RB SE TOMAN JUNTOS PARA FORMAR UN RESTO ESPIRO EN QUE R Y S SON 0-4 CON LA CONDICION DE QUE R+S HA DE SER 1 PERO NO5; Y XA ES -CH2-, -CHF, -CF2; -NR15-, -O-, O -S(=O)T-, EN QUE T ES 0,1; RC Y RD SON LOS MISMOS QUE RA Y RB EXCEPTO QUE UNO DE ELLOS DEBE SER -H; R1 Y R2 SON -H, R1 Y R2 SON -H, -F, -CL, CN, -NOP2, ALQUILO(C1-C4), ALQUINILO(C2-C4), ALQUILO(C1-C3)FLUORADO, -OR16 O -C(=O)NR22AR22B; R3 ES -H, ALQUILO(C1-C4), FENILO, BENCILO O -OR16; R4, R5 Y R6 SON(A)-H, -F, -CL, ALQUILO(C2-C4), -R16, -OR16, -S(=O)PR6, -S(=O)R16, -C(=O)OR16, -OC(=O)R16CN, -NO2, C(=O)NR16R17, -OC(=O)NR16R17, -NR22AC(=O)NR16R17, -NR22AC(=NR12)NR16R17, -NR22AC(=NCN)NR16R17, -NR22AC(=N-NO2)NR16R17, -C=NR22A)NR16R17, -CH2C(=NR22A)NR16R17, -OC(=NR22A)NR16R17, -OC(=N-NO2)NR16R17 -NR16R17, -CH2NR16R17, -NR22AC(=O)R16, -NR22AC(=O)OR16, =NOR16, -NR22AS(=O)R17, -S(=O)PNR16R17; O -CH2C(=NR22)NR16R17; EN QUE P ES 0,1 O 2; (B)ALQUILO(C1-C4)O ALCOXI(C1-C4)SUSTITUIDO CON 0-3 DE -F O -CL; O 0 O 1 DE ALCOXI(C1-C2)-CARBONILO, ALQUIL(C1-C2)-CARBONILO O ALQUIL(C1-C2)-CARBONILOXI; O (C)FENILO, BENCILO, FURANILO, TETRAHIDROFURANILO, OXETANILO, TIENILO, TETRAHIDROTIENILO, PIRROLILO, PIRROLIDINILO, OXAZOLILO, OXAZOLIDINILO, ISOXAZOLILO, ISOXAZOLIDINILO, TIAZOLILO, TIAZOLIDINILO, ISOTIAZOZLILO, ISOTIAZOLIDINILO, PIRAZOLILO, PIRAZOLIDINILO, OXAZIAZOLILO, TIADIAZOLILO, IMIDAZOLIDINILO,, PIRIDINILO, PIRAZINILO, PIRIMIDINILO, PIRIDAZINILO, PIPERIDINILO, PIPERAZINILO, TRIAZOLILO, TRIAZINILO, TETRAZOLILO, PIRANILO, AZETIDINILO, MORFOLINILO, PARATIAZINILO, INDOLILO, BENZO[B]FURANILO, 2,3-DIHIDRO-BENZOFURANILO, 2-H-CROMENILO, CROMANILO, BENZOTIENILO, 1H-INDALILO, BENCIMIDAZOLILO, BENZOXAZOLILO, BENZOISOXAZOLILO, BENZOTIAZOLILO, QUINOLINILO, ISOQUINOLINILO, FTALAZINILO, QUINAZOLINILO, QUINOXALINILO O PURINILO, TODOS ELLOS SUSTITUIDOS CON 0-2 DE R14 O (D)R5 Y R6 SSE TOMAN CONJUNTAMENTE PARA FORMAR UN RESTO DE FORMULAS PARCIALES(1.3.1)HASTA(1.3.15); D ES UN GRUPO DE FORMULAS PARCIALES(1.1.1)HASTA(1.1.9):VER FORMULAS EN QUE Q ES 2 O 3, R9 HA DE SER -H; V ES 0-1 W3 ES -O-, N(R9)- O -OC(=O)-; R7 ES (A) -H; (B)ALQUILO(C1-C6), ALQUENILO(C2-C6) O ALQUINILO(C2-C6), TODOS ELLOS SUSTITUIDOS CON 0-3 DE R10; (C)-(CH2)U-CICLOALQUILO(C3-C7)EN QUE U ES 0-2 SUSTITUIDO CON 0-3 DE R10; O (D)FENILO O BENCILO SUSTITUIDO CON 0-3 DE R10; R8 ES (A)TETRAZOL-5-ILO, 1,2,4-TRIAZOL-3-ILO, 1,2,4-TRIAZOL-3-ON-5-ILO, 1,2,3-TRIAZOL-5-ILO, IMIDAZOL-2-ILO, IMIDAZOL-4-ILO, IMIDAZOLIDIN-2-ON-4-ILO, 1,2,4-OXADIAZOL-3-ILO, 1,2,4-OXADIAZOL-5-ON-3-ILO, 1,2,4-OXADIAZOL-5-ILO, 1,2,4-OXADIAZOL--ON-5-ILO, 1,3,4-OXADIAZOLILO, 1,3,4-OXADIAZOL-2-ON-5-ILO, OXAZOLILO, ISOXAZOLILO, PIRROLILO, PIRAZOLILO, SUCCIMIDILO, GLUTARIMIDILO, PIRROLIDONILO, 2-PIPERIDONILO, 2-PIRIDONILO, PIRIDAZIN-3-ONILO, TIADIAZOLILO, PARATIAZINILO; (B)INDOLILO, INDOLINILO, ISOINDOLINILO, BENZO[B]FURANILO, 2,3-DIHIDROBENZOFURANILO, 2-H-CROMENILO, CROMANILO, BENZOTIENILO, 1H-INDAZOLILO, BENCIMIDAZOLILO, BENZOPXAZOLILO, BENZOISOXAZOLILO, BENZOTIAZOLILO, BENZOTRIAZOLILO, BENZOTRIAZINILO, QUINAZOLINILO, QUINOXALINILO, PIRAZOLO[3,4-D]PIRIMIDINILO, PIRIMIDO[4,5-D]PIRIDIMIDINILO, IMIDAZO[1,2-A]PIRIDINILO, PIRIDO-PIRIDINILO, PTERIDINILO O PURINILO, TODOS ELLOS OPCIONALMENTE SUSTITUIDOS EN UN ATOMO DE CABRONO CON R14, EN UN ATOMO DE NITROGENO CON R15 Y TODAS SUS FORMAS TAUTOMERAS EN UN ATOMO DE AZUFGRE CON 0-2 ATOMOS DE OXIGENO; R9 ES -H, ALQUIL(C1-C4)CICLOALQUILO(C3-C7)FENILO, BENCILO; -C(=O)OR16, -C(=O)R16, -OR16, ALQUIL(C1-C2)-OR16 O ALQUIL(C1-C2)-C(=O)OR16; O(C)-O-P)=O)(OH)2(FOSFORICO), -PG¿H(=O)OH(FOSFINICO), -P(=O)(OH)2(FOSFONICO)(OH)-O-ALQUILO(C1-C4)(ALQUIL FOSFONO)VER FORMULA, -S(=O)2NHS(=O)2R25, EN QUE R25 ES -H, -ALQUIL(C1-C4), FENILO O -OR16, J1 Y J2 SON UN RESTO QUE COMPRENDE UN SISTEMA ANULAR DE CARBONOS SATURADO O INSATURADO QUE ES MONOCICLICO DE 3 A 7 MIEMBROS, O QUE ES POLICICLICO CONDENSADO O DISCONTINUO DE 7 A 12 MIEMBROS; EN QUE OPCIONALMENTE UN ATOMO DE CARBONO DE DICHO SISTEMA ANULAR DE CARBONOS PUEDE SER REEMPLAZADO POR UN HETEROATOMO SELECCIONADO ENTRE N, O Y S; Y CUANDO SE SELECCIONA N, OPCIONALMENTE UN SEGUNDO ATOMO DE CARBONO DE ESTE PUEDE SER REEMPLAZADO POR UN HETEROATOMO SELECCIONADO ENTRE N, O Y S; O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE ESTE.
SV2002000861A 2001-01-31 2002-01-30 Derivados de eteres utiles como agentes inhibidores de las isozimas pde4 ref. pc11896arms/bb SV2003000861A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26530401P 2001-01-31 2001-01-31

Publications (1)

Publication Number Publication Date
SV2003000861A true SV2003000861A (es) 2003-01-13

Family

ID=23009905

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2002000861A SV2003000861A (es) 2001-01-31 2002-01-30 Derivados de eteres utiles como agentes inhibidores de las isozimas pde4 ref. pc11896arms/bb

Country Status (34)

Country Link
US (3) US6828333B2 (es)
EP (1) EP1373258B1 (es)
JP (1) JP2004518689A (es)
KR (1) KR20030070150A (es)
CN (1) CN1527830A (es)
AP (1) AP2002002415A0 (es)
AR (1) AR032522A1 (es)
AT (1) ATE305467T1 (es)
BG (1) BG107960A (es)
BR (1) BR0116845A (es)
CA (1) CA2436544A1 (es)
CR (1) CR7043A (es)
CZ (1) CZ20031902A3 (es)
DE (1) DE60113731T2 (es)
EA (1) EA200300652A1 (es)
EE (1) EE200300361A (es)
ES (1) ES2248231T3 (es)
GT (1) GT200200012A (es)
HU (1) HUP0302891A2 (es)
IL (1) IL156460A0 (es)
IS (1) IS6847A (es)
MA (1) MA26984A1 (es)
MX (1) MXPA03006885A (es)
NO (1) NO20033399L (es)
NZ (1) NZ526531A (es)
OA (1) OA12541A (es)
PA (1) PA8537901A1 (es)
PE (1) PE20020846A1 (es)
PL (1) PL364910A1 (es)
SK (1) SK8942003A3 (es)
SV (1) SV2003000861A (es)
TN (1) TNSN03051A1 (es)
WO (1) WO2002060896A1 (es)
ZA (1) ZA200304893B (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20031902A3 (cs) * 2001-01-31 2004-07-14 Pfizer Products Inc. Etherové deriváty užitečné jako inhibitory isozymů PDE4
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6777432B1 (en) * 2001-09-04 2004-08-17 Darwin Molecular Corporation Pharmaceutical uses and synthesis of nicotinamides
IL160271A0 (en) 2001-09-19 2004-07-25 Altana Pharma Ag Pharmaceutical compositions containing pde4-inhibitors and nsaid
US20050158371A1 (en) * 2002-02-12 2005-07-21 Sumitomo Pharmaceuticals Co., Ltd. Novel external agent
JP2006516548A (ja) 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト 迅速ゲル化ポリマー組成物からの薬物送達法
WO2004067006A1 (en) * 2003-01-27 2004-08-12 Pharmacia Corporation Combination of a pde iv inhibitor and a tnf-alpha antagonist
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US20050186276A1 (en) * 2003-07-17 2005-08-25 Pfizer Inc Pharmaceutical formulations
GB0317484D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
US7132435B2 (en) 2003-07-25 2006-11-07 Pfizer Inc. Compounds
GB0317471D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Novel compounds
GB0317516D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as PDE4 inhibitors
US7153870B2 (en) 2003-07-25 2006-12-26 Pfizer Inc. Nicotinamide derivatives useful as PDE4 inhibitors
US20050187278A1 (en) * 2003-08-28 2005-08-25 Pharmacia Corporation Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
US7776893B2 (en) * 2003-09-05 2010-08-17 Nycomed Gmbh Use of PDE4 inhibitors for the treatment of diabetes mellitus
JP3997255B2 (ja) 2004-02-13 2007-10-24 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー アンドロゲンレセプターモジュレーター
WO2005100305A1 (en) * 2004-04-13 2005-10-27 Warner-Lambert Company Llc Androgen modulators
WO2005102990A1 (en) 2004-04-22 2005-11-03 Warner-Lambert Company Llc Androgen modulators
BRPI0513020A (pt) 2004-07-08 2008-04-22 Warner Lambert Co moduladores de andrÈgenio, seus usos, composição farmacêutica, formulação farmacêutica tópica e artigo de fabricação
WO2006094942A1 (en) * 2005-03-08 2006-09-14 Nycomed Gmbh Roflumilast for the treatment of diabetes mellitus
NZ560269A (en) * 2005-03-08 2010-12-24 Nycomed Gmbh Roflumilast for the treatment of diabetes mellitus
RS52944B (sr) * 2005-04-19 2014-02-28 Takeda Gmbh Roflumilast za lečenje pulmonarne hipertenzije
TW200724139A (en) 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
TWI385169B (zh) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
KR20080065704A (ko) 2005-11-09 2008-07-14 콤비네이토릭스, 인코포레이티드 의학적 이상의 치료 방법들, 조성물들, 및 키트들
JP2009524590A (ja) * 2005-12-20 2009-07-02 ティカ レーケメデル アーベー 薬物動態学的プロフィールの向上を有するコルチコステロイドを送達するための方法およびシステム
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
JP2009536667A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
MX2009002496A (es) 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
US8569229B2 (en) * 2008-02-07 2013-10-29 The Children's Hospital Of Philadelphia Compositions and methods which modulate G-protein signaling for the treatment of inflammatory disorders such as asthma and allergic conjunctivitis
RU2011108587A (ru) 2008-08-05 2012-09-10 Те Огайо Стейт Юниверсити Рисерч Фаундейшн (Us) Новые метилендиоксифенольные соединения и их применение для лечения заболеваний
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
US20100280031A1 (en) * 2009-04-30 2010-11-04 Paul David Lipid formulation of apoptosis promoter
SG176571A1 (en) * 2009-05-19 2012-01-30 Vivia Biotech Sl Methods for providing personalized medicine tests ex vivo for hematological neoplasms
TWI532484B (zh) * 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
TWI471321B (zh) * 2009-06-08 2015-02-01 亞培公司 Ｂｃｌ－２族群抑制劑之口服醫藥劑型
US8697691B2 (en) * 2009-12-21 2014-04-15 Vanderbilt University Alkyl 3-((2-amidoethyl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate analogs as selective M1 agonists and methods of making and using same
SG10201500152UA (en) * 2009-12-22 2015-03-30 Abbvie Inc Abt-263 capsule
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
US9433680B2 (en) 2013-01-31 2016-09-06 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9446131B2 (en) 2013-01-31 2016-09-20 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US8778365B1 (en) 2013-01-31 2014-07-15 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9452173B2 (en) 2013-01-31 2016-09-27 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
EP3039126B1 (en) 2013-08-26 2019-10-09 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Small molecule cellular reprogramming to generate neuronal cells
CN108299418A (zh) * 2017-09-14 2018-07-20 刘双伟 一种抗过敏和哮喘的噻唑基烟酰胺类化合物的合成方法
US11174220B2 (en) 2019-12-13 2021-11-16 Inspirna, Inc. Metal salts and uses thereof
IT201900025126A1 (it) * 2019-12-20 2021-06-20 Sildeha Swiss S A Uso di derivati dell’acido ialuronico nella rigenerazione dei tessuti ossei e cartilaginei
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
KR102404883B1 (ko) 2020-11-30 2022-06-07 (주)이노보테라퓨틱스 벤즈브로마론을 포함하는 켈로이드 또는 비대흉터 예방 또는 치료용 약학 조성물
CN114907315B (zh) * 2022-05-17 2023-09-12 重庆医科大学 Selitrectinib中间体的合成方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2140772A5 (en) 1971-06-07 1973-01-19 Aries Robert Phenoxynicotinoylaminophenols - analgesics tranquillisers antipyretics, anti-inflammatories and antirheumatics
US4270946A (en) * 1979-10-01 1981-06-02 Stauffer Chemical Company N-Aryl,2-phenoxy nicotinamide compounds and the herbicidal use thereof
US4692185A (en) * 1986-01-13 1987-09-08 Stauffer Chemical Company N-(ortho-substituted) benzyl, 3-trifluoromethylphenoxy nicotinamides as herbicides
US4861891A (en) 1988-08-31 1989-08-29 Pfizer Inc. Antidepressant N-substituted nicotinamide compounds
ATE174343T1 (de) 1991-02-27 1998-12-15 Lacer Sa Antihypertensive n-(alpha-substituiertes pyridyl)-carbonyldipeptide
US5602438A (en) * 1991-02-28 1997-02-11 Robert Bosch Gmbh Roll commutator for electric motors and dynamos, and method of manufacturing it
DE4200323A1 (de) 1992-01-09 1993-07-15 Bayer Ag Herbizide und pflanzennematizide mittel auf basis von mercaptonicotinsaeurederivaten
EP0633776B1 (en) 1992-04-02 2001-05-09 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
EP0710109B1 (en) 1993-06-18 2004-09-15 Smithkline Beecham Corporation Method for identifying a PDE IV inhibitor
JP3406689B2 (ja) 1994-03-15 2003-05-12 株式会社大塚製薬工場 ナフチリジン及びピリドピラジン誘導体
US5618027A (en) * 1994-07-20 1997-04-08 Nevrekar; Venkatesh R. Gate valve
WO1996019990A1 (en) 1994-12-23 1996-07-04 Smithkline Beecham Corporation 4,4-(disubstituted)cyclohexan-1-carboxylate monomers and related compounds
TW429148B (en) * 1995-10-27 2001-04-11 Pfizer Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases
EP0796619A1 (en) * 1996-03-21 1997-09-24 Merrell Pharmaceuticals Inc. Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol in treating depressive disorders and bipolar disorders
FR2754178B1 (fr) * 1996-10-04 2002-08-23 Adir Utilisation de la sulbutiamine pour l'obtention de compositions pharmaceutiques utiles dans le traitement de certains troubles psychomoteurs et psycho-intellectuels
GB9622386D0 (en) 1996-10-28 1997-01-08 Sandoz Ltd Organic compounds
US5922557A (en) 1997-01-09 1999-07-13 Merck & Co., Inc. System for stably expressing a high-affinity camp phosphodiesterase and use thereof
TR200001847T2 (tr) 1997-04-04 2002-06-21 Pfizer Products Inc. Nikotinamid Türevleri
GB9715584D0 (en) * 1997-07-23 1997-10-01 Eisai Co Ltd Compounds
UA67753C2 (uk) 1997-10-10 2004-07-15 Смітклайн Бічам Корпорейшн Спосіб отримання заміщених 4-феніл-4-ціанциклогексанових кислот
AR015966A1 (es) 1997-10-17 2001-05-30 Smithkline Beecham Corp Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
AR015190A1 (es) 1997-10-23 2001-04-18 Smithkline Beecham Corp Un polimorfo cristalino de 1,3-diciclopropilmetil-8-aminoxantina, procedimiento para su preparacion, composiciones farmaceuticas que lo contienen y su usopara la manufactura de un medicamento
CA2398182C (en) * 2000-01-31 2007-03-13 Pfizer Products Inc. Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes
ATE269860T1 (de) * 2000-01-31 2004-07-15 Pfizer Prod Inc Pyrimidinylcarboxamiden als inhibitoren der pde4 isoenzyme
CZ20031902A3 (cs) * 2001-01-31 2004-07-14 Pfizer Products Inc. Etherové deriváty užitečné jako inhibitory isozymů PDE4

Also Published As

Publication number Publication date
BR0116845A (pt) 2004-02-25
CZ20031902A3 (cs) 2004-07-14
ZA200304893B (en) 2004-06-24
PA8537901A1 (es) 2002-10-31
HUP0302891A2 (hu) 2003-12-29
AR032522A1 (es) 2003-11-12
WO2002060896A1 (en) 2002-08-08
EA200300652A1 (ru) 2003-12-25
JP2004518689A (ja) 2004-06-24
CA2436544A1 (en) 2002-08-08
MXPA03006885A (es) 2003-11-13
US6828333B2 (en) 2004-12-07
AP2002002415A0 (en) 2002-03-31
OA12541A (en) 2006-06-05
NO20033399D0 (no) 2003-07-30
KR20030070150A (ko) 2003-08-27
PE20020846A1 (es) 2002-09-21
SK8942003A3 (en) 2004-10-05
US7183293B2 (en) 2007-02-27
EE200300361A (et) 2003-12-15
US20070161681A1 (en) 2007-07-12
MA26984A1 (fr) 2004-12-20
PL364910A1 (en) 2004-12-27
NO20033399L (no) 2003-09-25
ES2248231T3 (es) 2006-03-16
DE60113731D1 (de) 2006-02-09
AU2002222428A2 (es) 2002-08-12
US20050049258A1 (en) 2005-03-03
IL156460A0 (en) 2004-01-04
CN1527830A (zh) 2004-09-08
EP1373258B1 (en) 2005-09-28
IS6847A (is) 2003-06-16
DE60113731T2 (de) 2006-06-29
BG107960A (en) 2004-10-29
CR7043A (es) 2003-11-25
TNSN03051A1 (fr) 2005-12-23
ATE305467T1 (de) 2005-10-15
US20030027845A1 (en) 2003-02-06
NZ526531A (en) 2005-02-25
GT200200012A (es) 2002-09-02
EP1373258A1 (en) 2004-01-02

Similar Documents

Publication Publication Date Title
SV2003000861A (es) Derivados de eteres utiles como agentes inhibidores de las isozimas pde4 ref. pc11896arms/bb
ECSP034709A (es) Derivados de eteres utiles como agentes inhibidores de las isozimas pde4
ES2983048T3 (es) Compuestos heterocíclicos como inhibidores de PAD
AR040230A1 (es) Indol, azaindol, y heterociclos relacionados de 4-alquenil piperidina
AR088919A2 (es) Derivados de pirazol, composiciones que contienen dichos compuestos y uso
ES2602798T3 (es) Compuestos diméricos de agonistas de los receptores de FGF (FGFR), proceso para la preparación de los mismos y uso terapéutico de los mismos
ES2561210T3 (es) Derivados de piridina pirazolo como inhibidores de la NADPH oxidasa
AR086144A1 (es) Derivados de pirrolotriazinona como inhibidores de pi3k
AU2004249511B2 (en) Processes for the preparation of 1-[(benzoimidazole-1yl) quinolin-8-yl] piperidin-4-ylamine derivatives
AR045690A1 (es) Compuestos biaril heterociclicos y metodos para preparar y utilizar los mismos
CO5570669A2 (es) Pirazolopirimidinas como agentes terapeuticos
DE60203652D1 (de) Nikotinsäureamid-Derivate und ihre Mimetika als Inhibitoren von PDE4-Isozyms
AR062224A1 (es) Tetrazolilos macrociclicos como inhibidores de serina proteasa ns3 del virus de hepatitis c y composiciones farmaceuticas que los comprenden.
JP2005532297A5 (es)
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
PA8609201A1 (es) Piridinonas sustituidas
EA200800476A1 (ru) Макроциклические ингибиторы вируса гепатита с
AR059425A1 (es) Amidas ciclicas condensadas del acido bencensulfonico, un metodo para su preparacion, composiciones farmaceuticas que las contienen y el empleo de las mismas en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de l-cpt1
BR122012009489B8 (pt) processo para produzir 2-etóxi-1-{[2’-(5-oxo-4,5-diidro-1,2,4-oxadiazol-3-il)bifenil-4-il]metil}-1h-benzimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metila ou um sal do mesmo, composição farmacéutica, e, uso
AR018330A1 (es) Composiciones farmaceuticas que comprenden macrolidos como agentes activos para la terapia y profilaxis de las enfermedades de la piel
AR041303A1 (es) Compuestos de piperidinil-imidazopiridina n-sustituidos como moduladores del receptor 5-ht4"
AR046782A1 (es) Compuestos heterociclicos de biarilo halogenados, composiciones farmaceuticas que los contienen, metodos para su elaboracion y su uso como medicamentos.
AR076310A1 (es) 4-azetidinil-1-heteroaril ciclohexanos sustituidos antagonistas de ccr2,composiciones farmaceuticas que los contienen, proceso para prepararlos y uso de los mismos en el tratamiento de diabetes,obesidad y otras enfermedades.
PE55298A1 (es) Derivados de pirrolopirrolona
PE20081892A1 (es) Nuevos analogos de amino-piridina como agentes antitromboticos

Legal Events

Date Code Title Description
FD Lapse